← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Targazyme, Inc.
Carlsbad, CA
$3,291,637
Total funding
8
Grants
Funding over time
peak $1.1M · FY2008–16$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,291,637 · 8
By mechanism
R43$1,608,257 · 6
R44$1,526,626 · 1
R41$156,754 · 1
Investigators at Targazyme, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD$1,059,489
R44 · FY2015 · CA
A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD$467,137
R44 · FY2016 · CA
Ex Vivo Fucosylation of Cord Blood with FTVII & Enhanced Hematopoietic Recovery$347,580
R43 · FY2011 · HL
Increased Therapeutic Potential of Migrating Neural Stem Cells & ASC101 Treatment$335,440
R43 · FY2013 · NS
Enhanced Engraftment with Fucosylation of Cord Blood & Mesenchymal Stem Cells$290,908
R43 · FY2011 · HL
Therapeutic Potential & Targeted Homing of ECSOD-MSCs in Animal Model of Mucositi$224,932
R43 · FY2014 · DE
Novel cell-based Restorative Approach in Treatment of Diabetes-related Retinopath$215,739
R43 · FY2014 · EY
Novel Approach to Enhance Cord Blood-Mediated Bone Marrow Homing and Engraftment$193,658
R43 · FY2008 · CA
ASC101 Enhancement of Regenerative Capacity of Amniotic Fluid-derived Stem Cells$156,754
R41 · FY2012 · HL